Study of an IRAK4 blocker for blood cancers
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests a new drug called AZD2962 for people with certain blood cancers (MDS or CMML) that have come back or not responded to treatment. The drug blocks a protein called IRAK4, which may help stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of blood cancer called MDS or CMML that has come back or not responded to treatment, and you've had at least one prior therapy.
- Your blood or bone marrow cancer cells (blasts) are less than 20%.
- You are well enough to be up and about (ECOG performance status 0, 1, or 2).
- You have symptoms from your disease that need treatment and can be measured.
- You are willing to provide a bone marrow sample before starting the study.
- You have not taken other IRAK-blocking drugs or certain other medications before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug, AZD3632, either alone or with other cancer treatments, for people with advanced blood cancers that have specific genetic changes (like KMT2Ar, NPM1m, or others that cause HOX over-expression). The goal is to see if it can help when standard treatments have stopped working.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
This trial tests a new drug called axatilimab, given alone or with another drug, for people with certain blood cancers that are advanced or hard to treat. The goal is to see if this combination can help control the disease.
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
Hear when a new Haematologic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.